Side-by-side · Research reference
GHK-CuvsIGF-DES
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED8/47 cited
BAnimal-StrongHUMAN-REVIEWED8/60 cited
GHK-Cu
Tripeptide · Skin / Hair / Wound Healing
SQ or topical · Local · Daily or 2-3×/week
IGF-DES
IGF-1 Analogue · Truncated N-Terminal
~10×Potency vs IGF-1
ReducedIGFBP binding
ResearchStatus
Injection (local or systemic) · Research protocols onlyBredehöft 2008
01Mechanism of Action
Parameter
GHK-Cu
IGF-DES
Primary target
Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018
IGF-1 receptor (IGF1R)Shields 2007
Pathway
Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018
IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation
Downstream effect
Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018Zink 2003
Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation
Feedback intact?
Replaces declining endogenous levels
Unknown — no human endocrine feedback data
Origin
Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018
Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008
Antibody development
—
—
02Dosage Protocols
Parameter
GHK-Cu
IGF-DES
Standard SQ dose
1–2 mg / dayPickart 2018
Anecdotal injectable range; topical creams use 0.1–2% solutions.
—
Topical concentration
0.1–2.0% in serum / cream
—
Frequency
Daily or 2–3× per week (SQ)
Variable — daily to multiple times daily in research
Lower / starter dose
0.5 mg / day SQ
—
Duration
8–12 weeks for visible skin / hair effect
—
Reconstitution
Bacteriostatic water; light-protected
—
Timing
No specific time; evening preferred for topicals
—
Half-life
Hours (estimated; rapid tissue uptake)
Shorter than IGF-1 due to reduced IGFBP binding
Rapid tissue uptake, limited systemic circulation.
Research dose range
—
10–100 ng/mL (in vitro); μg doses (animal models)
Highly context-dependent; no standardized human protocol.
Route
—
Subcutaneous or intramuscular (local injection favored)
Local delivery maximizes tissue-specific uptake.
Human data
—
None — no clinical trials
03Metabolic / Fat Loss Evidence
Parameter
GHK-Cu
IGF-DES
Primary mechanism
—
Indirect via muscle hypertrophy → metabolic rate elevation
Direct lipolysis
—
Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic
Prostate model
—
Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002
Context-specific anti-proliferative effect, not fat loss.
04Side Effects & Safety
Parameter
GHK-Cu
IGF-DES
Injection site reaction
Erythema, mild pruritus (common)
Expected — erythema, irritation, local swelling
Topical irritation
Mild redness, transient stinging
—
Copper accumulation
Theoretical with very high chronic doses
—
Allergic reaction
Rare hypersensitivity to copper
—
Pregnancy / OB
Avoid topical and SQ — insufficient data
—
Wilson disease
Contraindicated
—
Hypoglycemia risk
—
Theoretical — IGF-1 axis enhances glucose uptake
Mitogenic risk
—
Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002
Edema / Fluid retention
—
Possible via sodium retention (IGF-1 axis effect)
Human safety data
—
Absent — no human trials, all effects theoretical or extrapolated
Unknown long-term effects
—
No chronic dosing studies in humans; endocrine, metabolic consequences unknown
Absolute Contraindications
GHK-Cu
- ·Wilson disease (copper-overload disorder)
- ·Pregnancy / breastfeeding
- ·Known copper hypersensitivity
IGF-DES
- ·Active malignancy or history of cancer (mitogenic risk)
- ·Pregnancy / lactation (no safety data)
- ·Hypoglycemia disorders
Relative Contraindications
GHK-Cu
- ·Hemochromatosis (copper-iron crosstalk theoretical)
- ·Concurrent copper-chelator therapy
IGF-DES
- ·Diabetes mellitus (unpredictable glucose effects)
- ·Renal or hepatic impairment (clearance unknown)
- ·Edema-prone conditions (heart failure, nephrotic syndrome)
05Administration Protocol
Parameter
GHK-Cu
IGF-DES
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.
Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.
2. Injection site
SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.
Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.
3. Timing
Anytime; evening preferred. Topical: apply to clean dry skin.
Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.
Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.
5. Needle
30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.
27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.
6. Monitoring
—
Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.
06Stack Synergy
GHK-Cu
+ BPC-157
ModerateGHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.
- GHK-Cu
- 1–2 mg SQ · daily near wound
- BPC-157
- 250–500 mcg SQ · daily near wound
- Primary benefit
- Combined ECM rebuilding + angiogenesis for tissue repair
IGF-DES
+ BPC-157
ModerateDes(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- BPC-157
- 250–500 mcg SQ, daily or twice daily
- Frequency
- Daily or per research protocol
- Primary benefit
- Accelerated muscle repair, enhanced hypertrophy, connective tissue support
+ TB-500
ModerateTB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- TB-500
- 2–5 mg SQ, 2× weekly
- Frequency
- Per research cycle
- Primary benefit
- Muscle hypertrophy, injury recovery, vascular support